Cleveland Clinic Abu Dhabi: A New Era of Cardiac Excellence

By HEOR Staff Writer

November 5, 2023

Centre of Excellence for Adult Cardiac Surgery

A Landmark Achievement in Healthcare

The Department of Health – Abu Dhabi (DoH) has declared Cleveland Clinic Abu Dhabi, a component of the M42 network, as a Centre of Excellence (CoE) for Adult Cardiac Surgery (ACS). This significant announcement is a testament to Abu Dhabi’s commitment to delivering world-class healthcare services to its community and reinforces its standing as a leading healthcare destination.

Centre of Excellence for Adult Cardiac Surgery: A New Standard in Cardiac Care

As an ACS CoE, Cleveland Clinic Abu Dhabi offers a comprehensive range of cardiac surgery and structural heart disease interventions. These services are provided by a team of highly experienced cardiologists and some of the world’s most reputable surgeons. The Clinic boasts dedicated cardiac surgery ICU facilities and cardiac operating rooms, supported by core services that include multidisciplinary cardiovascular medicine, interventional cardiology, electrophysiology, and a pioneering structural heart programme.

H.E. Dr. Noura Al Ghaithi, Undersecretary of the DoH, emphasised the importance of the CoE programme in elevating healthcare outcomes and increasing competitiveness across the sector. She expressed delight at the announcement and looked forward to the continuous contributions from partners to enhance the healthcare sector’s excellence.

Hasan Jasem Al Nowais, Chairman of Cleveland Clinic Abu Dhabi and Managing Director and Group Chief Executive Officer of M42, highlighted the Clinic’s establishment as a regional and global benchmark for complex care. He reiterated their commitment to excellence and the vision of providing world-class complex care to patients in the UAE and across the region.

Reference url

Recent Posts

Immunotherapy for Liver Cancer
Exploring Immunotherapy for Liver Cancer through the EMERALD-3 Trial

By HEOR Staff Writer

June 5, 2026

Immunotherapy for liver cancer has advanced substantially with the EMERALD-3 Phase III trial, which showed that
biosimilar policy development
Multistakeholder Engagement in Biosimilar Policy Development

By João L. Carapinha

June 3, 2026

In advancing biosimilar policy development across Europe, the AUGMENT Biosimilars project identifies effective measures to overcome barriers to uptake, lower costs, and expand patient access to follow-on biological medicines. The three-day
pharmacy network value
Community Pharmacy Network Value in Enhancing Healthcare Access and Efficiency

By João L. Carapinha

June 3, 2026

A landmark study underscores the pharmacy network value in Portugal, revealing how community pharmacies deliver accessible care, reduce pressure on the National Health Service (SNS), and generate significant economic and environmental returns. With a presence in every municipality, these pharmaci...